HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

May 15th 2025

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 14th 2025

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

Dr Tarantino on the Expanding Role of T-DXd in HER2+ Breast Cancer

May 13th 2025

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

Dr Tarantino on Early-Stage HER2+ Breast Cancer Risk Stratification

May 12th 2025

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Navigating Early-Line Treatment Options for HER2+ Metastatic Breast Cancer

May 9th 2025

Panelists discuss how the treatment landscape for early HER2-positive metastatic breast cancer has evolved, with taxane-pertuzumab-trastuzumab as first-line standard of care and T-DXd supplanting T-DM1 as the preferred second-line treatment.

HER2+ Breast Cancer Management: Navigating GnRH Agonist Choice and Patient Experience

May 9th 2025

Panelists discuss how different gonadotropin-releasing hormone (GnRH) agonists like leuprolide and goserelin are equally efficacious for ovarian function suppression but differ in administration methods, needle size, and patient comfort.

T-DXd Followed by THP Improves pCR Rate in HER2+ Early Breast Cancer

May 7th 2025

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1

May 6th 2025

The next-generation ADC ARX788 is under investigation in the phase 2 ACE-Breast-03 trial of patients with T-DXd–pretreated HER2-positive breast cancer.

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2025

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

April 29th 2025

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression

April 28th 2025

Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.

Optimizing Therapy in HR+/HER2+ Breast Cancer: Balancing Endocrine, HER2-Targeted, and Chemotherapy Options

April 28th 2025

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Dr Desai on the Role of Palbociclib in HR+, HER2+ Metastatic Breast Cancer

April 25th 2025

Neelam Desai, MD, discusses the role of a palbociclib-containing regimen in HR-positive, HER2-positive metastatic breast cancer.

Dr Ali on the Potential SOC Role of Palbociclib Plus Anti-HER2 and Endocrine Therapy in HER2+ Breast Cancer

April 24th 2025

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Japanese Approval Is Sought for T-DXd in HER2+ Advanced Solid Tumors

April 24th 2025

Japan’s Ministry of Health has received a supplemental new drug application for T-DXd for HER2-positive advanced or recurrent solid tumors.

Extended Adjuvant Pyrotinib Shows Promising Efficacy After Trastuzumab-Based Therapy in HER2+ Breast Cancer

April 23rd 2025

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.

Dr Tarantino on Trials Reshaping the Perioperative Treatment Algorithm for HER2+ Breast Cancer

April 22nd 2025

Paolo Tarantino, MD, the clinical impact of the KATHERINE trial in reshaping the post-surgical treatment algorithm for HER2+ breast cancer care.

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment

April 21st 2025

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.